Does the media favor MNPR or LENZ?

In the previous week, Monopar Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 4 mentions for Monopar Therapeutics and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.34 beat Monopar Therapeutics' score of 0.71 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LENZ or CADL?

In the previous week, Candel Therapeutics had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.34 beat Candel Therapeutics' score of 0.25 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLYM or LENZ?

In the previous week, Climb Bio had 9 more articles in the media than LENZ Therapeutics. MarketBeat recorded 10 mentions for Climb Bio and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.34 beat Climb Bio's score of 0.83 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LENZ or DRUG?

In the previous week, Bright Minds Biosciences had 6 more articles in the media than LENZ Therapeutics. MarketBeat recorded 7 mentions for Bright Minds Biosciences and 1 mentions for LENZ Therapeutics. Bright Minds Biosciences' average media sentiment score of 1.53 beat LENZ Therapeutics' score of 1.34 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

LENZ Therapeutics (LENZ) Competitors

$5.30 -0.46 (-7.99%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.41 +0.11 (+2.15%)

As of 07/31/2026 07:46 PM Eastern

Compare

LENZ vs. MNPR, AURA, CADL, CLYM, and DRUG

Should you buy LENZ Therapeutics stock or one of its competitors? MarketBeat compares LENZ Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENZ Therapeutics include Monopar Therapeutics (MNPR), Aura Biosciences (AURA), Candel Therapeutics (CADL), Climb Bio (CLYM), and Bright Minds Biosciences (DRUG).

How does LENZ Therapeutics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Monopar Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
LENZ Therapeutics	$19.09M	8.70	-$82.13M	-$3.60	N/A

Monopar Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Monopar Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 4 mentions for Monopar Therapeutics and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.34 beat Monopar Therapeutics' score of 0.71 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics currently has a consensus price target of $112.08, indicating a potential upside of 3.45%. LENZ Therapeutics has a consensus price target of $29.80, indicating a potential upside of 462.26%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Monopar Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Monopar Therapeutics' return on equity of -12.84% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Summary

Monopar Therapeutics beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Aura Biosciences?

LENZ Therapeutics (NASDAQ:LENZ) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aura Biosciences has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Aura Biosciences	N/A	-78.12%	-64.08%

LENZ Therapeutics presently has a consensus price target of $29.80, indicating a potential upside of 462.26%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 192.44%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe LENZ Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, LENZ Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for LENZ Therapeutics and 0 mentions for Aura Biosciences. LENZ Therapeutics' average media sentiment score of 1.34 beat Aura Biosciences' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
LENZ Therapeutics	Positive
Aura Biosciences	Neutral

LENZ Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

LENZ Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.70	-$82.13M	-$3.60	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Summary

LENZ Therapeutics beats Aura Biosciences on 12 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Candel Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

LENZ Therapeutics currently has a consensus price target of $29.80, suggesting a potential upside of 462.26%. Candel Therapeutics has a consensus price target of $18.57, suggesting a potential upside of 85.53%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Candel Therapeutics had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.34 beat Candel Therapeutics' score of 0.25 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENZ Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, indicating that its share price is 152% less volatile than the broader market.

Candel Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.70	-$82.13M	-$3.60	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Candel Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Candel Therapeutics	N/A	-60.42%	-41.33%

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Candel Therapeutics beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Climb Bio presently has a consensus target price of $22.00, suggesting a potential upside of 84.87%. LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 462.26%. Given LENZ Therapeutics' higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Climb Bio has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Climb Bio's return on equity of -31.45% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Climb Bio had 9 more articles in the media than LENZ Therapeutics. MarketBeat recorded 10 mentions for Climb Bio and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.34 beat Climb Bio's score of 0.83 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has higher earnings, but lower revenue than LENZ Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
LENZ Therapeutics	$19.09M	8.70	-$82.13M	-$3.60	N/A

Summary

Climb Bio beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Bright Minds Biosciences?

LENZ Therapeutics (NASDAQ:LENZ) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

LENZ Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.34, meaning that its share price is 634% less volatile than the broader market.

In the previous week, Bright Minds Biosciences had 6 more articles in the media than LENZ Therapeutics. MarketBeat recorded 7 mentions for Bright Minds Biosciences and 1 mentions for LENZ Therapeutics. Bright Minds Biosciences' average media sentiment score of 1.53 beat LENZ Therapeutics' score of 1.34 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LENZ Therapeutics presently has a consensus price target of $29.80, indicating a potential upside of 462.26%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 96.33%. Given LENZ Therapeutics' higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Bright Minds Biosciences' return on equity of -20.58% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Bright Minds Biosciences has lower revenue, but higher earnings than LENZ Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.70	-$82.13M	-$3.60	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Summary

Bright Minds Biosciences beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LENZ vs. The Competition

Export

Metric	LENZ Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$166.18M	$12.78B	$7.17B	$12.47B
Dividend Yield	N/A	2.73%	2.59%	9.45%
P/E Ratio	-1.47	799.05	282.25	24.66
Price / Sales	8.70	738.07	583.21	88.77
Price / Cash	N/A	73.15	71.23	59.99
Price / Book	0.58	10.92	11.09	5.90
Net Income	-$82.13M	$2.82B	$3.50B	$336.31M
7 Day Performance	-3.28%	-0.06%	-0.24%	0.09%
1 Month Performance	-10.02%	-3.91%	-3.70%	-5.17%
1 Year Performance	-82.31%	156.13%	61.98%	18.61%

LENZ Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LENZ LENZ Therapeutics	2.9507 of 5 stars	$5.30 -8.0%	$29.80 +462.3%	-82.3%	$166.18M	$19.09M	N/A	110
MNPR Monopar Therapeutics	1.4404 of 5 stars	$109.09 -1.1%	$112.08 +2.7%	+166.3%	$730.79M	N/A	N/A	10	High Trading Volume
AURA Aura Biosciences	2.0391 of 5 stars	$7.05 -1.5%	$20.50 +190.8%	+4.0%	$728.88M	N/A	N/A	50
CADL Candel Therapeutics	2.538 of 5 stars	$9.68 -2.8%	$18.57 +91.9%	+59.1%	$709.25M	N/A	N/A	60	Analyst Forecast Gap Down
CLYM Climb Bio	2.8656 of 5 stars	$12.29 -3.9%	$22.00 +79.0%	+720.7%	$703.76M	N/A	N/A	9	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENZ Therapeutics (LENZ) Competitors

LENZ vs. MNPR, AURA, CADL, CLYM, and DRUG

How does LENZ Therapeutics compare to Monopar Therapeutics?

Summary

How does LENZ Therapeutics compare to Aura Biosciences?

Summary

How does LENZ Therapeutics compare to Candel Therapeutics?

Summary

How does LENZ Therapeutics compare to Climb Bio?

Summary

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENZ Therapeutics (LENZ) Competitors

LENZ vs. MNPR, AURA, CADL, CLYM, and DRUG

How does LENZ Therapeutics compare to Monopar Therapeutics?

Which has better valuation & earnings, MNPR or LENZ?

Which has more risk & volatility, MNPR or LENZ?

Do institutionals and insiders have more ownership in MNPR or LENZ?

Does the media favor MNPR or LENZ?

Do analysts prefer MNPR or LENZ?

Is MNPR or LENZ more profitable?

Summary

How does LENZ Therapeutics compare to Aura Biosciences?

Do insiders & institutionals believe in LENZ or AURA?

Is LENZ or AURA more profitable?

Do analysts rate LENZ or AURA?

Does the media prefer LENZ or AURA?

Which has more volatility and risk, LENZ or AURA?

Which has higher valuation and earnings, LENZ or AURA?

Summary

How does LENZ Therapeutics compare to Candel Therapeutics?

Do analysts rate LENZ or CADL?

Does the media favor LENZ or CADL?

Which has more volatility & risk, LENZ or CADL?

Which has preferable valuation and earnings, LENZ or CADL?

Is LENZ or CADL more profitable?

Do insiders and institutionals hold more shares of LENZ or CADL?

Summary

How does LENZ Therapeutics compare to Climb Bio?

Do analysts rate CLYM or LENZ?

Which has more risk and volatility, CLYM or LENZ?

Is CLYM or LENZ more profitable?

Do insiders & institutionals hold more shares of CLYM or LENZ?

Does the media favor CLYM or LENZ?

Which has stronger earnings & valuation, CLYM or LENZ?

Summary

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Which has more risk & volatility, LENZ or DRUG?

Does the media prefer LENZ or DRUG?

Do analysts rate LENZ or DRUG?

Do insiders and institutionals have more ownership in LENZ or DRUG?

Is LENZ or DRUG more profitable?

Which has stronger earnings & valuation, LENZ or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools